Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC
July 2nd 2000This multicenter study enrolled 73 patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC). The study design was based on the hypothesis that the non-overlapping toxicities of a 3-drug